| [1] | 李道娟,李倩,贺宇彤.结直肠癌流行病学趋势[J].肿瘤防治研究,2015,42(3):305. |
| [2] | 宋卫峰,王雷,蔡讯,等.晚期结直肠癌病人氟尿嘧啶剂量与血药浓度和生存的关系[J].肿瘤,2013,33(9):820. |
| [3] | SAAM J,CRICHFIELD GC,HAMILTON SA,et al.Body surface areabased dosing of 5-fluorouracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on FOLFOX regimens[J].Clin Colorectal Cancer,2011,10(3):203. |
| [4] | KALDATE RR,HAREGEWOIN A,GRIER CE,et al.Modeling the 5-FU area under the curve cersus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6[J].Oncologist,2012,17(3):296. |
| [5] | 刘杨.奥沙利铂联合替吉奥治疗晚期大肠癌疗效观察[J].中华实用诊断与治疗杂志,2014,28(10):1035. |
| [6] | UNDEVIA SD,GOMEZ-ABUIN G,RATAIN MJ,et al.Pharmacokinetic variability of anticancer agents[J].Nature Rev Cancer,2005,5(6):447. |
| [7] | KIRKWOOD JM,ENSMINGER W,ROSOWSKY A,et al.Comparison of pharmacokinetics of 5-fluorouracil and 5-fluorouracil concurrent thymidine infusions in a Phase I trial[J].Cancer Res,1980,40(1):107. |
| [8] | GAMELIN E,DELVA R,JACOB J,et al.Individual 5-fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage:results of a multicenter randomized trial in patients with metastatic colorectal cancer[J].J Clin Oncol,2008,26(13):2099. |
| [9] | 张红雨,赵春临,叶延伟.氟尿嘧啶血药浓度监测对于结直肠癌病人化疗疗效的研究进展[J].河南医学研究,2016,25(2):260. |
| [10] | 智玲玲,李智英.奥沙利铂联合5-FU/亚叶酸钙改良时辰化疗治疗晚期结直肠癌疗效观察[J].医药论坛,2014,35(1):61. |